Table 1.
Gene Set Enrichment Analysis (GSEA) for Ep5 Cells Treated with Platelets
| Gene sets | NES | Nominal p-value | FDR |
|---|---|---|---|
| EMT Signatures | |||
| BLICK_EMT-SIG_UP | 1.993 | <0.001 | <0.001 |
| TAUBE_EMT_UP | 1.328 | 0.060 | 0.060 |
| TAUBE_EMT_DN | −2.081 | <0.001 | <0.001 |
| ONDER_CDH1_TARGETS_2_UP | 1.526 | <0.001 | 0.044 |
| ONDER_CDH1_TARGETS_2_DN | −1.832 | <0.001 | 0.006 |
| TGFβ Signatures | |||
| GIAMPIERI_TGFB_UP | 1.992 | <0.001 | <0.001 |
| GIAMPIERI_TGFB_DN | −2.576 | <0.001 | <0.001 |
| VALCOURT_TGFB_UP | 1.813 | <0.001 | 0.005 |
| VALCOURT_TGFB_DN | −1.926 | <0.001 | <0.001 |
| Cancer Stem Cell Signatures | |||
| CREIGHTON_CSC_UP | 1.675 | <0.001 | <0.001 |
| CREIGHTON_CSC_DN | −1.778 | <0.001 | <0.001 |
| Tumor progression and Metastasis Signatures | |||
| VANTVEER_BREAST_CANCER_POOR_PROGNOSIS | 1.953 | <0.001 | <0.001 |
| JAEGER_METASTASIS_UP | 1.875 | <0.001 | 0.003 |
Enrichment of gene sets from the literature (see supplementary information for references). Positive normalized enrichment score (NES) indicates enrichment in platelet-treated Ep5 cells; negative NES indicates enrichment in untreated Ep5 cells. FDR (false discovery rate).